Copyright
©The Author(s) 2022.
World J Clin Oncol. Jul 24, 2022; 13(7): 652-662
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.652
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.652
Total dose | P value | |||
66-68 Gy | 70 Gy | 72 Gy | ||
Variable | n (%) | |||
Patients, n (%) | 59 (21.1) | 131 (50) | 89 (31.9) | |
Median age, range | 63.3 (50-74) | 62.7 (48-75) | 62.3 (41-75) | |
PSA preRT | 0.36 | |||
≤ 0.4 ng/mL | 26 (44.1%) | 59 (48.8%) | 49 (55.7%) | |
>0.4 ng/mL | 33 (55.9%) | 62 (51.2%) | 39 (44.3%) | |
cT stage | 0.43 | |||
cT1 | 38 (67.9%) | 65 (57%) | 53 (66.2%) | |
cT2 | 18 (32.1%) | 46 (40.4%) | 26 (32.5%) | |
cT3 | 0 (0%) | 3 (2.6%) | 1 (1.2%) | |
pT stage | 0 | |||
pT1-T2 | 45 (80.4%) | 94 (75.2%) | 41 (47.1%) | |
pT3-T4 | 11 (19.6%) | 31 (24.8%) | 46 (52.9%) | |
pN stage | 0.32 | |||
N0 | 25 (42.4%) | 60 (46.9%) | 42 (48.3%) | |
N1 | 1 (1.7%) | 5 (3.9%) | 1 (1.1%) | |
Nx | 33 (55.9%) | 63 (49.2%) | 44 (50.6%) | |
GS (biopsy) | 0.06 | |||
≤ 6 | 31 (53.4%) | 67 (52.8%) | 32 (37.6%) | |
7 | 25 (43.1%) | 53 (41.7%) | 42 (49.4%) | |
≥ 8 | 2 (3.4%) | 7 (5.5%) | 11 (12.9%) | |
GS (prostatectomy) | 0.01 | |||
≤ 6 | 7 (17.9%) | 28 (29.5%) | 9 (12.2%) | |
7 | 27 (69.2%) | 49 (51.6%) | 41 (55.4%) | |
≥ 8 | 5 (12.8%) | 18 (18.9%) | 24 (32.4%) | |
Margin status | 0.81 | |||
Positive | 33 (55.9%) | 74 (56.9%) | 54 (60.7%) | |
Negative | 26 (44.1%) | 56 (43.1%) | 35 (39.3%) | |
Hormonotherapy | 0 | |||
Yes | 28 (48.3%) | 50 (40.3%) | 15 (18.1%) | |
No | 30 (51.7%) | 74 (59.7%) | 68 (81.9%) | |
RT indication | 0.68 | |||
Adjuvant RT | 19 (32.2%) | 41 (31.5%) | 33 (37.1%) | |
Salvage RT | 40 (67.8%) | 90 (68.5%) | 56 (62.9%) |
Total dose | |||||||||
66-68 Gy (n = 54) | 70 Gy (n = 86) | 72 Gy (n = 36) | |||||||
Grade (G) | GI | GII | GIII | GI | GII | GIII | GI | GII | GIII |
Acute GU toxicity | 11 (20.4%) | 2 (3.7%) | 0 | 17 (19.8%) | 4 (4.7%) | 0 | 3 (8.3%) | 2 (5.6%) | 1 (2.8%) |
Acute GI toxicity | 16 (29.6%) | 2 (3.7%) | 0 | 23 (26.7%) | 6 (6.9%) | 0 | 2 (5.6%) | 1 (2.8%) | 0 |
Total dose | ||||||
66-68 Gy (n = 5) | 70 Gy (n = 26) | 72 Gy (n = 51) | ||||
Grade (G) | GI-II | GIII | GI-II | GIII | GI-II | GIII |
Chronic GU toxicity | 0 | 0 | 3 (11.5%) | 1 (3.8%) | 11 (13.4%) | 1 (1.2%) |
Chronic GI toxicity | 0 | 0 | 2 (7.7%) | 0 | 1 (2%) | 0 |
- Citation: Hervás-Morón A, Domínguez-Rullán J, Santana VD, Valero M, Vallejo C, Sancho S, Fuentes JDG, Cámara Gallego M, López-Campos F. Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data. World J Clin Oncol 2022; 13(7): 652-662
- URL: https://www.wjgnet.com/2218-4333/full/v13/i7/652.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i7.652